产品说明书
ETA antagonist 1
 |
同义名 : | - |
| CAS号 : | 161801-60-1 | |
| 货号 : | A108645 | |
| 分子式 : | C20H25N3O3S | |
| 纯度 : | 98% | |
| 分子量 : | 387.496 | |
| MDL号 : | N/A | |
| 存储条件： |
粉末 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | ETA antagonist 1 is a ETA selective antagonist with an IC50 of 0.08 μM. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00796510 | Pulmonary Arterial Hypertensio... 展开 >>n Pulmonary Hypertension 收起 << | Phase 3 | Terminated(Safety Issue The tr... 展开 >>ial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury) 收起 << | - | United States, California ... 展开 >> Pfizer Investigational Site Fountain Valley, California, United States, 92708 Romania Pfizer Investigational Site Cluj Napoca, Romania, 400 001 Ukraine Pfizer Investigational Site Kyiv, Ukraine 收起 << |
| NCT01658410 | Coronary Artery Disease ... 展开 >> Aorto-coronary Bypass Grafting 收起 << | Phase 2 | Unknown | December 2016 | Austria ... 展开 >> Medical University of Vienna Vienna, Austria, 1090 收起 << |
| NCT00001527 | - | Completed | - | United States, Maryland ... 展开 >> National Heart, Lung and Blood Institute (NHLBI) Bethesda, Maryland, United States, 20892 收起 << | |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.58mL 0.52mL 0.26mL |
12.90mL 2.58mL 1.29mL |
25.81mL 5.16mL 2.58mL |
